Once-Daily Linagliptin Reduces Blood Glucose Long Term For Diabetes Type 2 Patients
News
Results of a 102 week Phase III investigation for linagliptin (trade name Trajenta® in Europe) were announced today, and showed significant and durable reductions in blood glucose levels for adults who suffer from type 2 diabetes. The study which was presented at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD), demonstrated that the DPP-4 inhibitor linagliptin displayed a promising safety profile and reduced HbA1c levels by 0.8% over the long term in individuals treated with linagliptin for the entire investigation period.
|
|
In Mouse Model, Decoding Infidelity Linked To Type 2 Diabetes
News
Type 2 diabetes is an extremely common chronic condition characterized by high levels of sugar in the blood as a result of either insufficient production of the hormone insulin or an inability of cells to respond to insulin. A combination of genetic and environmental factors causes an individual to develop type 2 diabetes.
|
|
|
|
|